CNMD Q1 2026: A GI Exit Refocuses Growth, Elevates Revenue Forecast, and Elevates the EPS Narrative

Performance snapshot

• Revenue: Sales of $317.0 million, down 1.3% year over year as reported; down 2.9% in constant currency. The delta reflects a $15.5 million drag from the exit of certain GI products.
• Domestic vs. international: Domestic revenue down 5.8% YoY, driven by GI portfolio actions; International revenue up 4.7% as reported (and +1.0% in constant currency), with a $0.3 million GI exit drag.
• EPS: GAAP diluted EPS of $0.45, up from $0.19 in Q1 2025. Adjusted diluted EPS of $0.89, versus $0.95 in the year-ago quarter.
• Outlook and revenue forecast: The company raises guidance for full-year 2026 organic revenue growth to about 5.0% to 6.5% (constant currency). Full-year 2026 revenue is now expected to be $1.350 billion to $1.375 billion, up from a prior range of $1.345 billion to $1.375 billion. An estimated 40 to 50 basis points of favorable foreign exchange is baked in versus the prior assumption of 0 to 50 bps.
• GI divestiture impact: Updated guidance reflects $14.5 million to $17.5 million in gastroenterology-revenue, lower than the prior range of $21.0 million to $25.0 million due to the divestiture of the remaining GI portfolio.

What it signals for CNMD and peers

The headline numbers read like a strategic pivot: a first quarter heavily affected by the GI portfolio exit, offset by a confident reorientation toward higher-growth, higher-margin arenas—minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. The EPS narrative is mixed in the near term: GAAP EPS jumped to $0.45 from $0.19, but adjusted EPS softened to $0.89 from $0.95 a year earlier. This dichotomy is exactly the kind of thing investors might parse as the company’s core earnings power evolves, while non-GAAP metrics – the darling of many med-tech disclosures – reflect ongoing adjustments from portfolio changes.

From a “revenue forecast” perspective, the uplift in organic growth guidance to 5.0%–6.5% (from 4.5%–6.0%) signals management’s confidence that, once GI divestiture effects fade, demand dynamics and pricing can support a healthier growth trajectory. The shift in total 2026 revenue guidance to $1.350–$1.375 billion, coupled with a projected FX tailwind, suggests management expects operating leverage to offset the one-time drag from GI exits.

For the EPS consensus and earnings surprise narrative, the lack of explicit consensus data in the release means traders will likely look to subsequent analyst notes for directional revisions. The juxtaposition of a higher revenue forecast with a lower adjusted EPS relative to the prior year could be read either as a normalization after the GI exit or as a sign that the cleaner growth story depends more on volume of higher-margin products than on aggressive pricing or cost-cutting—not a bad bet, but one that needs execution discipline.

Management commentary

“Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”

The tone is telling: the company is pruning the portfolio to allocate capital toward products and segments with clearer growth paths, while also leveraging a favorable FX backdrop to support the top line.

Implications for CNMD’s sector peers

The GI divestiture is part of a broader trend in medical devices: portfolio rationalization to focus on higher-velocity product categories. If CNMD’s update proves durable, other companies with similar non-core assets may accelerate divestitures or co-opting of acquisitions to reposition for legitimacy of growth in core franchises. Expect more attention from investors to long-cycle launches in minimally invasive platforms and adjacencies around surgical robotics, with a watchful eye on foreign exchange effects and domestic demand cycles, which can swing as currency moves and hospital procurement calendars align.

Risks and takeaways

Key uncertainties include the pace of demand in domestic markets versus international markets, continued progress in converting GI customers to the new product mix, and the ability to sustain margin expansion as the company scales its higher-growth segments. The lack of a clearly stated EPS consensus in the release means investors will be evaluating the legitimacy of the adjusted earnings narrative against external estimates, and the market may reward or penalize CNMD based on how well the revised growth trajectory translates into realized earnings power over the next several quarters.